Skip to main content

Advertisement

SpringerLink
Log in

Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The authors have investigated the expression of the microcephalin (MCPH1) protein to evaluate its prognostic importance in breast cancer. Microcephalin is a damage response protein involved in the regulation of BRCA1 and BRCA2. BRCA1 mutations are often associated with basal-like breast cancer, which are also often negative for oestrogen receptor (ER), progesterone receptor (PR) and HER2. MCPH1 immunohistochemistry was performed on 319 breast cancers prepared as tissue microarray and correlated with pathology, survival, ER, PR, HER2, EGFR, CK5/6, CK14 and BRCA1 expression. After performing continuous data analysis, mean microcephalin expression decreased with increasing grade (P < 0.006). Mean microcephalin expression was lower in ER/PR negative (P < 0.001) and triple negative cancers (P < 0.004). Conversely, an association with HER2-positive cancers was also identified (P < 0.034). Reduced microcephalin also correlated with reduced nuclear BRCA1 staining (P < 0.001). No association was identified with basal markers. After dichotomising the data into low and high microcephalin expression, reduced expression was identified in 29% (93/319) of breast cancers. An association with low expression was identified in invasive ductal carcinomas with breast cancer-specific survival (BCSS) (P = 0.052). Multivariate analysis of ductal carcinomas showed that microcephalin, together with lymph node involvement and tumour size were independent predictors of BCSS (P = 0.037). Microcephalin expression is reduced in 29% of breast cancers, particularly in higher grade tumours and BRCA1-negative cases. Microcephalin is an independent predictor of BCSS in invasive ductal breast cancer patients and may prove to be a useful biomarker for the identification of aggressive breast cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jackson AP, Eastwood H, Bell SM et al (2002) Identification of Microcephalin, a protein implicated in determining the size of the human brain. Am J Hum Genet 71:136–142

    Article  PubMed  CAS  Google Scholar 

  2. Lin S-Y, Elledge SJ (2003) Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113:881–888

    Article  PubMed  CAS  Google Scholar 

  3. Koonin EV, Altschul SF, Bork P (1996) BRCA1 protein products: functional motifs. Nat Genet 13(3):266–268

    Article  PubMed  CAS  Google Scholar 

  4. Wood JL, Singh N, Mer G, Chen J (2007) MCPH1 functions in a H2AX-dependent but MDC1 independent pathway in response to DNA damage. J Biol Chem 282(48):35416–35423

    Article  PubMed  CAS  Google Scholar 

  5. Ria R, Dai H, Multani AS et al (2006) BRIT1 regulates early damage response, chromosomal integrity and cancer. Cancer Cell 10(2):145–157

    Article  Google Scholar 

  6. Wu X, Mondal G, Wang X et al (2009) Microcephalin regulates BRCA2 and Rad51-associated DNA double-strand break repair. Cancer Res 69:5531–5536

    Article  PubMed  CAS  Google Scholar 

  7. Xu X, Lee J, Stern DF (2004) Microcephalin is a DNA damage response protein involved in regulation of CHK1 and BRCA1. J Biol Chem 279:34091–34094

    Article  PubMed  CAS  Google Scholar 

  8. Lin SY, Rai R, Li K et al (2005) BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1-Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proc Natl Acad Sci USA 102:15105–15109

    Article  PubMed  CAS  Google Scholar 

  9. Tibelius A, Marhold J, Zentgraf H et al (2009) Microcephalin and pericentrin regulate mitotic entry via centrosomal-associated Chk1. J Cell Biol 185(7):1149–1157

    Article  PubMed  CAS  Google Scholar 

  10. Yang SZ, Lin FT, Lin WC (2008) MCPH1/BRIT1 cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis. EMBO Rep 9:907–915

    Article  PubMed  CAS  Google Scholar 

  11. Lin S-Y, Liang Y, Li K (2010) Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair and cancer suppression. Yonsei Med J 51(3):295–301

    Article  PubMed  CAS  Google Scholar 

  12. Qin L-X (2002) Chromosomal aberrations related to metastasis of human solid tumours. World J Gastroenterol 8(5):769–776

    PubMed  CAS  Google Scholar 

  13. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast cancer sub types in independent gene expression data sets. Proc Natl Acad Sci USA 11:5678–5685

    Google Scholar 

  14. Abd El-Reihm DM, Ball G, Pinder SE et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350

    Article  Google Scholar 

  15. Rakha EA, El Saved ME, Green AR et al (2007) Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression Histopathology 50(4):434–438

    CAS  Google Scholar 

  16. Turner NC, Reis-Fiho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25:5846–5853

    Article  PubMed  CAS  Google Scholar 

  17. Foulks WD, Stefansson IM, Chappuis PO (2004) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95(19):1482–1485

    Google Scholar 

  18. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26(15):2586–2590

    Article  Google Scholar 

  19. Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO (2008) Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Path 39:857–865

    Article  PubMed  CAS  Google Scholar 

  20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumour marker prognostic studies. J Clin Oncol 23(36):9067–9072

    Article  PubMed  Google Scholar 

  21. Breslow NE, Day NE (1987) Fitting models to continuous data. In: Breslow NE, Day NE (eds) Statistical methods in cancer research. The design and analysis of cohort studies, vol 2. IARC Scientific Publications, Lyon, pp 199–299

    Google Scholar 

  22. Altman DG, Lyman GH (1998) Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52:289–303

    Article  PubMed  CAS  Google Scholar 

  23. Dejmek J, Iglehart JD, Lazaro JB (2009) DNA-dependent protein kinase (DNA-PK) dependent cisplatin induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT. Mol Cancer Res 7(4):581–591

    Article  PubMed  CAS  Google Scholar 

  24. Rai R, Phadnis A, Haralkar S et al (2008) Differential regulation of centrosome integrity by DNA damage response proteins. Cell Cycle 7(14):2225–2233

    Article  PubMed  CAS  Google Scholar 

  25. Mueller CR, Roskelley CD (2003) Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res 5(1):45–52

    Article  PubMed  CAS  Google Scholar 

  26. Fong PC, Boss DS, Yap TA et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumours from BRCA mutation carriers. N Eng J Med 361:123–134

    Article  CAS  Google Scholar 

  27. Trimborn M, Ghani M, Walther DJ et al (2010) Establishment of a mouse model with misregulated chromosome condensation due to defective Mcph1 function. PLoS One 5(2):e9242

    Article  PubMed  Google Scholar 

  28. Liang Y, Gao H, Lin SY et al (2010) BRIT1/MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice. PLoS Genet 6:e1000826

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from Yorkshire Cancer Research grant number L317 (SMB & VS), and the Breast Cancer Campaign 2007NovPR53 (SMB & VS). MK is supported by a scholarship from the Egyptian government. RA is supported by a scholarship from the Saudi Arabian government.

Author information

Authors and Affiliations

  1. Leeds Institute of Molecular Medicine, University of Leeds, Wellcome Trust Brenner Building, St. James’s University Hospital, Leeds, LS9 7TF, UK

    Julie Richardson, Mohamed Kamal, Rawiah Alisary, Valerie Speirs & Sandra M. Bell

  2. St James’s Institute of Oncology, St James’s University Hospital, Leeds, LS9 7TF, UK

    Abeer M. Shaaban & Clare Walker

  3. Department of Pathology, School of Molecular Medical Sciences, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Derby Road, Nottingham, NG5 1PB, UK

    Ian O. Ellis & Andrew R. Green

  4. Department of Zoology, University of Benha, Benha, Egypt

    Mohamed Kamal

Authors
  1. Julie Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abeer M. Shaaban
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed Kamal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rawiah Alisary
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Clare Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ian O. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Valerie Speirs
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andrew R. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sandra M. Bell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandra M. Bell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richardson, J., Shaaban, A.M., Kamal, M. et al. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Breast Cancer Res Treat 127, 639–648 (2011). https://doi.org/10.1007/s10549-010-1019-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-1019-4

Keywords

Search

Navigation